Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion type Assertion NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_head.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion description "[Here, we show that TP53-CDKN1A double-mutant bladder cancer cell lines, 647V and RT-112, have a remarkable increase in p-Chk1 levels and G2-M arrest in response to gemcitabine treatment, with a heightened sensitivity to combination treatment with gemcitabine and either Chk1 inhibitor PF477736 or AZD7762, in comparison with other bladder cancer cell lines (either TP53 or p21 deficient).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_provenance.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion evidence source_evidence_literature NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_provenance.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion SIO_000772 25349305 NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_provenance.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion wasDerivedFrom befree-2016 NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_provenance.
- NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_assertion wasGeneratedBy ECO_0000203 NP1233064.RA7iZb2xw4vbaQKSKE6m6heTPFAbMBTt76Bw7o0Pp_HbY130_provenance.